1
|
Fitzpatrick Z, Leborgne C, Barbon E, Masat E, Ronzitti G, van Wittenberghe L, Vignaud A, Collaud F, Charles S, Simon Sola M, Jouen F, Boyer O, Mingozzi F. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction. Mol Ther Methods Clin Dev 2018; 9:119-129. [PMID: 29766022 PMCID: PMC5948224 DOI: 10.1016/j.omtm.2018.02.003] [Citation(s) in RCA: 108] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Accepted: 02/08/2018] [Indexed: 12/30/2022]
Abstract
Pre-existing immunity to adeno-associated virus (AAV) is highly prevalent in humans and can profoundly impact transduction efficiency. Despite the relevance to AAV-mediated gene transfer, relatively little is known about the fate of AAV vectors in the presence of neutralizing antibodies (NAbs). Similarly, the effect of binding antibodies (BAbs), with no detectable neutralizing activity, on AAV transduction is ill defined. Here, we delivered AAV8 vectors to mice carrying NAbs and demonstrated that AAV particles are taken up by both liver parenchymal and non-parenchymal cells; viral particles are then rapidly cleared, without resulting in transgene expression. In vitro, imaging of hepatocytes exposed to AAV vectors pre-incubated with either NAbs or BAbs revealed that virus is taken up by cells in both cases. Whereas no successful transduction was observed when AAV was pre-incubated with NAbs, an increased capsid internalization and transgene expression was observed in the presence of BAbs. Accordingly, AAV8 vectors administered to mice passively immunized with anti-AAV8 BAbs showed a more efficient liver transduction and a unique vector biodistribution profile compared to mice immunized with NAbs. These results highlight a virtually opposite effect of neutralizing and binding antibodies on AAV vectors transduction.
Collapse
Affiliation(s)
- Zachary Fitzpatrick
- University Pierre and Marie Curie - Paris 6 and INSERM U974, 75005 Paris, France.,Genethon and INSERM U951, 91000 Evry, France
| | | | | | - Elisa Masat
- University Pierre and Marie Curie - Paris 6 and INSERM U974, 75005 Paris, France
| | | | | | | | | | | | - Marcelo Simon Sola
- University Pierre and Marie Curie - Paris 6 and INSERM U974, 75005 Paris, France.,Genethon and INSERM U951, 91000 Evry, France
| | - Fabienne Jouen
- Department of Immunology and Biotherapy, Normandie University, UNIROUEN, INSERM, U1234, 76000 Rouen University Hospital, Rouen, France
| | - Olivier Boyer
- Department of Immunology and Biotherapy, Normandie University, UNIROUEN, INSERM, U1234, 76000 Rouen University Hospital, Rouen, France
| | - Federico Mingozzi
- University Pierre and Marie Curie - Paris 6 and INSERM U974, 75005 Paris, France.,Genethon and INSERM U951, 91000 Evry, France
| |
Collapse
|